StockData
GENELUX Corp logo

GENELUX Corp (GNLX) stock

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.00+0.08 (+4.17%)

Close on Nov 17, 2026Market cap $90.49MP/E –Yield –

Earnings

Genelux's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Genelux's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2024ended Dec 31, 2024Mar 25, 2025before the open–––Release
Q4 FY2023ended Dec 31, 2023Feb 2, 2024during market hours–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Genelux has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Genelux puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Genelux filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?